Jiuzhitang announced on November 19 that the company's shareholding company, Beijing Kexin Meide Biomedical Technology Co., Ltd., and its affiliate company, Wallardzumab Injection, a Class 1 innovative antibody targeting glucagon receptors, recently obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of this product in type 1 diabetics in China. Indications: Subcutaneous injection once a week as an adjuvant treatment for insulin. It is suitable for treating type 1 diabetes in adults who cannot achieve target blood sugar with insulin alone.

Zhitongcaijing · 2d ago
Jiuzhitang announced on November 19 that the company's shareholding company, Beijing Kexin Meide Biomedical Technology Co., Ltd., and its affiliate company, Wallardzumab Injection, a Class 1 innovative antibody targeting glucagon receptors, recently obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of this product in type 1 diabetics in China. Indications: Subcutaneous injection once a week as an adjuvant treatment for insulin. It is suitable for treating type 1 diabetes in adults who cannot achieve target blood sugar with insulin alone.